Eversept Partners LP Makes New Investment in Vir Biotechnology, Inc. $VIR

Eversept Partners LP bought a new position in Vir Biotechnology, Inc. (NASDAQ:VIR) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 250,000 shares of the company’s stock, valued at approximately $2,240,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Quantinno Capital Management LP grew its stake in Vir Biotechnology by 144.3% in the first quarter. Quantinno Capital Management LP now owns 95,927 shares of the company’s stock worth $860,000 after purchasing an additional 56,655 shares during the period. OMERS ADMINISTRATION Corp purchased a new position in Vir Biotechnology during the first quarter valued at $149,000. Renaissance Technologies LLC boosted its holdings in shares of Vir Biotechnology by 23.9% during the 1st quarter. Renaissance Technologies LLC now owns 761,364 shares of the company’s stock valued at $6,822,000 after buying an additional 146,900 shares in the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of Vir Biotechnology during the 1st quarter valued at $1,010,000. Finally, Caxton Associates LLP purchased a new stake in shares of Vir Biotechnology in the 1st quarter worth about $112,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Insider Transactions at Vir Biotechnology

In other Vir Biotechnology news, Director Janet Napolitano sold 3,200 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.45, for a total transaction of $30,240.00. Following the completion of the sale, the director directly owned 21,216 shares in the company, valued at approximately $200,491.20. This trade represents a 13.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Vicki L. Sato sold 22,000 shares of Vir Biotechnology stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $10.05, for a total transaction of $221,100.00. Following the completion of the transaction, the director directly owned 1,078,391 shares of the company’s stock, valued at $10,837,829.55. This trade represents a 2.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 25,579 shares of company stock worth $254,922. 2.90% of the stock is currently owned by company insiders.

Vir Biotechnology Trading Up 1.3%

Vir Biotechnology stock opened at $8.80 on Tuesday. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $11.66. The company has a market capitalization of $1.48 billion, a price-to-earnings ratio of -2.81 and a beta of 1.62. The business’s fifty day simple moving average is $9.34 and its two-hundred day simple moving average is $8.89.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.84). Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 53.31%. The company had revenue of ($0.03) million for the quarter, compared to the consensus estimate of $55.49 million. During the same quarter in the previous year, the business earned ($0.88) earnings per share. On average, equities research analysts predict that Vir Biotechnology, Inc. will post -1.81 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on VIR shares. Morgan Stanley increased their price target on shares of Vir Biotechnology from $23.00 to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, June 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. Leerink Partners upped their price objective on shares of Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. Finally, Wall Street Zen downgraded shares of Vir Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.88.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.